Evidence map›Paper›PMID 29886354›Full record

Trial reportAtherosclerosis2018

Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis.

C Charles-Schoeman, G B Gugiu, H Ge, A Shahbazian, Y Y Lee, X Wang, D E Furst, V K Ranganath, M Maldonado, Terry Lee and 1 more

Abstract readClinical Trial, Phase IIComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Atherosclerosis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

C Charles-SchoemanUniversity of California Los Angeles, Los Angeles, CA, USA. Electronic address: ccharles@mednet.ucla.edu.
G B GugiuBeckman Research Institute of the City of Hope, Duarte, CA, USA.
H GeBeckman Research Institute of the City of Hope, Duarte, CA, USA.
A ShahbazianUniversity of California Los Angeles, Los Angeles, CA, USA.
Y Y LeeUniversity of California Los Angeles, Los Angeles, CA, USA.
X WangUniversity of California Los Angeles, Los Angeles, CA, USA.
D E FurstUniversity of California Los Angeles, Los Angeles, CA, USA.
V K RanganathUniversity of California Los Angeles, Los Angeles, CA, USA.
M MaldonadoBristol-Myers Squibb, Princeton, NJ, USA.
Terry LeeBeckman Research Institute of the City of Hope, Duarte, CA, USA.
S T ReddyUniversity of California Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USCity of Hope · USBeckman Research InstituteBristol-Myers Squibb (United States) · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
UCLA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR033176 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2011 to 2011
$15.5M
The role of PON2 and PON3 proteins in AtherosclerosisR01HL071776 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REDDY, SRINIVASA T. · 2003 to 2017
$4.8M
Mechanisms Linking Joint Inflammation and Atherosclerosis in Rheumatoid ArthritisR01HL123064 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHARLES-SCHOEMAN, CHRISTINA · 2015 to 2019
$2.7M
Molecular profiling of pro-inflammatory HDLR01HL082823 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REDDY, SRINIVASA T. · 2007 to 2011
$1.9M
HDL Function as a Biomarker for Atherosclerotic Risk in Rheumatoid ArthritisK23HL094834 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHARLES-SCHOEMAN, CHRISTINA · 2009 to 2013
$693k
NCI NIH HHS P30 CA033572NCRR NIH HHS UL1 RR033176NHLBI NIH HHS K23 HL094834NHLBI NIH HHS R01 HL071776NHLBI NIH HHS R01 HL082823NHLBI NIH HHS R01 HL123064
6 · The paper itself

Abstract

BACKGROUND AND

aimsTo evaluate changes in the high-density lipoprotein (HDL) proteome and HDL function in active rheumatoid arthritis (RA) patients initiating therapy with abatacept or adalimumab in the Abatacept Versus Adalimumab Comparison in Biologic-Naïve RA Subjects with Background Methotrexate (AMPLE) study.

methodsUltra high-pressure liquid chromatography (UHPLC) coupled with ion mobility mass spectrometry (LC-IM-MS) was used to analyze proteins associated with immunoaffinity-captured HDL from plasma of 30 patients with RA randomized to either abatacept (n = 15) or adalimumab (n = 15) therapy. Paraoxonase 1 (PON1) activity, HDL anti-oxidant capacity, cholesterol profiles, and homocysteine levels were also measured at baseline and following treatment. Repeated-measures analyses were performed using mixed-effect linear models to model the within-subject covariance over time.

resultsIn models controlling for age, sex and treatment group, improvement in inflammation measured by decreases in CRP was associated with improvement in HDL function and changes in several HDL-associated proteins including significant decreases in lipopolysaccharide-binding protein, serum amyloid A-I (SAA-I) and inter-alpha-trypsin inhibitor heavy chain H4 (p values < 0.05). Improvement in disease activity was also associated with changes in multiple HDL-associated proteins. Adalimumab was associated with higher PON1 activity, HDL-associated serotransferrin, and HDL-associated immunoglobulin J chain, and lower HDL-associated SAA-I over time compared with abatacept.

conclusionsImprovement in inflammation associated with treatment of RA, using either abatacept or adalimumab in the AMPLE study, was associated with improvement in HDL function and significant alterations in the HDL proteome, including proteins involved in the immune response, proteinase inhibition, and lipid metabolism.

Indexed as

ProteomeAbataceptAdalimumabAdultAntirheumatic AgentsArthritis, RheumatoidBiomarkersChromatography, High Pressure LiquidFemaleHumansIon Mobility SpectrometryLipoproteins, HDLMaleMass SpectrometryMiddle AgedTime FactorsAbataceptAdalimumabAntirheumatic AgentsBiomarkersLipoproteins, HDLProteomeAbataceptAdalimumabHigh density lipoproteinsRheumatoid arthritis

Identifiers

PMID29886354
PMCPMC6113060
OpenAlexW2799570154

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.